PDF )   Rev Osteoporos Metab Miner. 2021; 13 (2): 98-99
DOI: 10.4321/S1889-836X2021000200008

León-Asuero-Moreno I1, García-Gómez FJ1, Borrego-Luque A2
1 Nuclear Medicine Service. Virgen Macarena University Hospital. Seville (Spain)
2 Oral and Maxillofacial Surgery Service. Virgen Macarena University Hospital. Seville (Spain)


We present the case of a 62-year-old woman with a history of a fibrohistiocytic variant of a pulmonary inflammatory myofibroblastic tumor treated by a lobectomy of the right lower lobe and lymphadenectomy of the intrapulmonary area and pulmonary ligament, and a history of tooth extraction 11 due to a vestibular fistula torpid.
In a control [18-F] FDG PET/CT study, a solitary hypermetabolic lesion suggestive of malignancy was observed in the gingival area of the upper jaw (Figure1 A-C) and 3D reconstruction (Figure 2).
Given the suspicion of malignancy, a partial maxillectomy of teeth 13-23 was carried out with placement of an obturator prosthesis. Analysis confirmed the metastatic etiology by observing hypercellular areas with a fasciculate pattern and broader sarcomatoid areas. Immunohistochemical analysis showed strong ALK expression, higher FLI1 expression, and lower CD10 and TLE1 expression. At present, the patient remains asymptomatic.
Inflammatory myofibroblastic tumor (IMT), also known as inflammatory pseudotumor, xanthoma, plasma cell granuloma, pseudosarcoma, lymphoid hematoma, myxoid hamartoma and inflammatory myofibrohistiocytic proliferation [1,2], is an uncommon neoplastic growth of mesenchymal proliferation and myofibroblast line at the expense of myofibroblasts. an obvious inflammatory infiltrate composed of plasma cells, lymphocytes, and eosinophils [1-4]. This has generally been considered a benign tumor. At present, it is considered a neoplasm of intermediate malignancy, however, as it has a tendency to local aggressiveness and recurrences and, on rare occasions, may trigger distant metastases [1-4]. The etiology is unknown at this point in time, although inflammation, autoimmunity and previous infections are suggested as possible causes [1-4]. IMT may be found in a wide variety of locations, the most common being the pulmonary location, followed by the abdominal, skin, soft tissue, genital, and mediastinum. It is typical of pediatric age and young adults [2].
Normally, IMT presents asymptomatically, being detected as an incidental finding in a radiological test, although it can occasionally produce symptoms secondary to mass effect and nonspecific symptoms such as weight loss, anemia or fever secondary to the production of cytokines (mainly IL-1) [3]. It is necessary to perform a differential diagnosis against other non-neoplastic entities such as reparative, autoimmune or postinfection processes [2,4].
The [18-F] FDG PET/CT study is a very useful diagnostic test in the evaluation of the cancer patient. [18-F] FDG is a glucose analog that accumulates in body cells in proportion to glucose utilization. The accumulation of [18-F] FDG in most tumor cells by over-expression of the GLUT-1 transporter is characteristic, although active inflammatory processes can also present a physiological increase in [18F] FDG in granulocytes and mononuclear cells. IMT can show a heterogeneous uptake of [18F] FDG that can be explained by the variability of cellularity, the rate of cell proliferation and nuclear atypia of tumor cells, as well as the composition, proportion and activation of inflammatory cells [1,3,4]. The treatment of choice is complete surgical resection, being curative in 90% of cases. It has been shown that previous steroidal or non-steroidal anti-inflammatory treatment can be useful to reduce tumor size, in local recurrences or in unresectable tumors [1-4].
In conclusion, we present the detection by an [18-F] FDG PET/CT study of a metastasis in the head and neck region due to a tumor that rarely presents distant metastatic involvement.

Conflict of interests: The authors declare no conflict of interest.



1. Ma C, Lu J, Chen G, Wang W, Su F, Su X. Inflammatory myofibroblastic tumor mimicking lymphoma on 18F-FDG PET/CT. Report of a case and review of the literature. Hell J Nucl Med. 2018;21(1):77-80.
2. Alshammari HK, Alzamami HF, Ashoor M, Almarzouq WF, Kussaibi H. A Rare presentation of inflammatory myofibroblastic tumor in the nasolabial fold. Case Rep Otolaryngol. 2019; 2019:3257697.
3. Díaz Silván A, Allende Riera A, Cabello García D, Vilahomat Hernández O, Martínez Gimeno E. Inflammatory myofibroblastic tumor 18F-FDG PET/CT findings. Rev Esp Med Nucl Imagen Mol. 2019; 2019;38(3):190-1.
4. Dong A, Wang Y, Dong H, Gong J, Cheng C, Zuo C, et al. Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation. Clin Nucl Med. 2014;39(2):113-21.